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Abstract
Background: Intake of fish oil rich in n-3 polyunsaturated fatty acids (PUFAs) is believed to be beneficial against
development of non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanisms remain unclear.
This study was to gain further understanding of the potential mechanisms of the protective effects of fish oil
against NAFLD.
Methods: Ten male Sprague–Dawley rats were fed a control diet (CON), a Western style high-fat and high-
cholesterol diet (WD), or a WD diet containing fish oil (FOH) for 16 weeks respectively. The development of liver
steatosis and fibrosis were verified by histological and biochemical examination. Hepatic transcriptome were
extracted for RNA-seq analysis, and particular results were confirmed by real-time polymerase chain reaction (PCR).
Results: The consumption of fish oil significantly ameliorated WD-induced dyslipidemia, transaminase elevation,
hepatic steatosis, inflammatory infiltration, and fibrosis. Hepatic RNA-Seq analysis showed that long-term intake of
fish oil restored the expression of circadian clock-related genes per2 and per3, which were reduced in WD fed
animals. Fish oil consumption also corrected the expression levels of genes involved in fatty acid and cholesterol
metabolism, such as Srebf1, Fasn, Scd1, Insig2, Cd36, Cyp7a1, Abcg5, Abcg8 and Pcsk9. Moreover, the expression levels
of pro-inflammation genes Mcp1, Socs2, Sema4a, and Cd44 in the FOH group were lower than that of WD group,
implying that fish oil protects the liver against WD-induced hepatic inflammation.
Conclusion: The present study demonstrates fish oil protects against WD-induced NALFD via improving lipid
metabolism and ameliorating hepatic inflammation. Our findings add to the current understanding on the benefits
of n-3 PUFAs against NAFLD.
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Background
Non-alcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease in developed countries,
and is present in 20-30 % of Western population. Its in-
cidence in the urban population of developing countries
such as China has also increased rapidly in the recent
decades[1–3]. The typical pathological features of
NAFLD include excessive triacylglycerol (TG) accumula-
tion and micro/macrolipid vesiculae formation in the
liver. The initial stage of the disease is simple steatosis;
approximately 30-40 % of patients progress to non-
alcoholic steatohepatitis (NASH) with or without cirrho-
sis [4–7].
The excessive intake of typical Western-style high-fat,
high-cholesterol, and high-sugar diets and lack of appro-
priate physical exercise are believed to lead to hepatic
steatosis; however, the reason for progression of simple
steatosis to non-alcoholic steatohepatitis (NASH) is still
unclear. Classical “two-hits” hypothesis and modified
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“multiple-hits” hypothesis suggest that TG accumulation
in liver combined with insulin resistance, endoplasmic
reticulum stress (ERS), oxidative stress, and hepatic in-
flammation lead to NASH, hepatocyte death, and liver
fibrosis [8, 9]. The saturated free fatty acids (FFAs) and
free-cholesterol accumulation in circulation and liver
contribute to the progression from simple steatosis to
NASH, owing to FFA-induced toll-like receptor (TLR) 4
activation, pro-inflammatory cytokines release, and lipid
overload-induced hepatocyte apoptosis, which is also
known as lipoapoptosis[10–13]. Diets with high fat con-
tent, especially saturated fatty acids, may promote the
development of NASH [14, 15].
Conversely, n-3 polyunsaturated fatty acids (PUFAs),
such as docosahexaenoic acid (DHA), have been found
to decrease liver fat content in children with NAFLD
and possess anti-inflammatory effects. Moreover, recent
studies indicated the benefits of n-3 PUFAs in lipid me-
tabolism modification, dyslipidemia improvement, and
hepatic inflammation mitigation, which may contribute
to the amelioration of NAFLD. A latest meta-analysis re-
view presented by Parker et al. [16] showed that dietary
n-3 PUFA supplements ameliorated the hepatic steatosis
and liver injury in adult NAFLD patients. In the present
study, we set up a Western style high-fat and high-
cholesterol diet (WD)-induced NAFLD rat model, aim
to study the protective effects of fish oil-enriched n-3
PUFAs against NAFLD. In order to get a prospective
view of fish oil induced hepatic gene expression change
in NAFLD rats, we constructed an RNA-sequencing–
based transcriptomic approach to investigate the poten-
tial molecular mechanisms.
Results
FOH had no effects on bodyweight change compared
with WD-fed rats
Male 8–9 weeks SD rats were placed on a normal chow
diet (CON), a high-saturated fat and high-cholesterol
Western style diet (WD) or a WD diet with 10 % fish oil
(w/w) (FOH) for 16 weeks. The rats fed high-calories di-
ets were significantly heavier than those fed CON (P <
0.01). On the other hand, fish oil had no significant ef-
fects on the bodyweight compared with WD-fed rats
(Table 1, Additional file 1: Figure S3).
FOH ameliorated WD-induced hyperlipidemia
The routine blood biochemical tests showed that neither
WD nor FOH had affected the fasting blood glucose
level compared with low-fat CON. However, compared
with the CON group, the plasma TG, total cholesterol
(Tch), low-density lipoprotein cholesterol (LDL-C), and
non-esterified fatty acid (NEFA) concentration in rats
fed WD increased by 90 %, 90 %, 216 %, and 61 %, re-
spectively (P < 0.05). The effects of WD on plasma lipid
levels were attenuated by fish oil feeding. Compared
with the WD group, the plasma TG, TCh, LDL-C, and
NEFA concentrations in the FOH group decreased by
48 %, 56 %, 84 %, and 18 %, respectively (P < 0.05). In
Table 1 Phenotypic comparison of rats fed the CON, WD, or FOH diets for 16 weeks
CON WD FOH
Body weight, g 381 ± 15 478 ± 14a 461 ± 15 a
Plasma variables
Glucose, mmol/L 7.42 ± 0.25 7.77 ± 0.22 7.75 ± 0.26
TG, mmol/L 0.61 ± 0.06 1.16 ± 0.16 a 0.56 ± 0.04b
TCh, mmol/L 1.51 ± 0.13 2.87 ± 0.21 a 1.25 ± 0.05 b
HDL-C, mol/L 0.74 ± 0.04 0.58 ± 0.03 0.52 ± 0.02
LDL-C, mmol/L 0.57 ± 0.02 1.8 ± 0.33 a 0.29 ± 0.05 b
NEFA, μmol/L 964.16 ± 65.73 1551.12 ± 88.06 a 1284.85 ± 25.59 a b
ALT, U/L 47.32 ± 1.31 68.4 ± 1.95 a 56.82 ± 1.63 a b
AST, U/L 94.74 ± 2.2 166.98 ± 9.37 a 120.12 ± 4.67 ab
GST, U/L 80 ± 1.78 104.25 ± 4.52 a 81.67 ± 1.21 b
SOD, U/L 175.95 ± 5.23 144.36 ± 5.75 a 161.82 ± 3.13b
Liver variables
Weight, g 13.08 ± 1.38 22.80 ± 4.22 a 21.69 ± 1.89 a
Liver to body weight ratio, % 3.09 ± 0.22 4.79 ± 0.62 a 4.43 ± 0.31 a
TG, μmol/mg protein 0.20 ± 0.05 0.5 ± 0.07 a 0.34 ± 0.10 b
TCh, μmol/mg protein 0.4 ± 0.01 1.19 ± 0.14 a 0.43 ± 0.03 b
TG: triacylglycerol, TCh: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, NEFA: non-esterified fatty acid,
ALT: alanine aminotransferase, AST: aspartate aminotransferase, GST: glutathione S- transferase, SOD: superoxide dismutase.
Values are expressed as mean ± SD; n = 10 in each treatment group. aP < 0.05 compared with CON, bP < 0.05 compared with WD.
Yuan et al. Lipids in Health and Disease  (2016) 15:20 Page 2 of 13
general, the intake of the WD for 16 weeks induced typ-
ical hyperlipidemia, which was compensated by fish oil
intake.
FOH decreased hepatic transaminase activities in WD-fed
rats
Plasma ALT and AST levels are important liver injury
markers. Compared with the CON group, the ALT and
AST levels in rats fed WD were significantly increased
(P < 0.05), whereas compared with the WD group, the
activity of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) in the FOH group was de-
creased by 17 % (P < 0.05) and 28 % (P < 0.05), respect-
ively. A similar result was observed in the Glutathione
S- transferase (GST) activity. WD feeding increased
GST activity compared with CON (P < 0.05), but the
levels of GST in the FOH and CON groups had no sig-
nificant difference.
FOH improved hepatic lipid metabolism in WD-fed rats
The liver-to-body weight ratio of rats in the WD group
was 4.79 %, which was significantly higher than that in
the CON group, which was 3.09 %, and the ratio in the
FOH group was 4.43 %, which was slightly lower than
the WD group ( all P < 0.05). The hepatic TG and TCh
in the WD group were 1.5-fold and 3-fold higher than
the CON group, respectively. The rats fed FOH pre-
sented 32 % and 64 % decreased hepatic TG and TCh
amounts compared with rats fed WD, respectively.
FOH alleviated liver inflammation in WD-fed rats
As shown in Fig. 1 A-F, hematoxylin and eosin (H&E)
staining illustrated that WD feeding induced severe
macrovesicular steatosis and inflammatory cell infiltra-
tion in the liver. FOH dramatically diminished liver stea-
tosis compared with that of WD group. Furthermore,
fish oil feeding reduced inflammatory cells infiltration
around portal area (Fig. 1A-F). A hepatic histological
NAFLD activity scoring system based on vesicular stea-
tosis, hepatocellular ballooning, lobular inflammation,
and fibrosis indicated that 16-week WD feeding induced
NASH in rats (NAS = 7.83), but the rats in the FOH
group only developed simple steatosis without steatohe-
patitis (NAS = 3.17) (Table 2). Additionally, western blot-
ting analysis indicated that WD feeding up-regulated the
hepatic pro-inflammatory cytokines level such as TNF-α
and IL-1β, which were rescued by fish oil feeding
(Fig. 1J).
Differentially expressed genes identified between two
groups
To analyze differentially expressed genes (DEGs), the
genes which were tested with fold change >2 and P <
0.01 in the EdgeR package were selected. Compared with
the CON group, there were 1379 DEGs found in the
WD group, within 827 genes upregulated and 522 down-
regulated (Additional file 1: Table S4). Compared with
the WD group, 711 DEGs were found in the FOH group,
among them, the expression of 378 genes was increased
and the others were decreased (Additional file 1: Table
S5). MA plot analysis showed the magnitude of distribu-
tion of significantly changed genes (Fig. 2). Furthermore,
via analyzing the overlapped genes between the WD and
FOH groups, we found that in the FOH group, the ex-
pression of 88 genes which decreased in the WD group
were rescued, and the expression of 149 genes increased
in the WD group were inhibited.
Functional enrichment of DEGs in FOH compared with
WD
The DAVID platform (data base including Gene ontol-
ogy, Interpro, and KEGG Gene functions) was adopted
for functional cluster. The results demonstrated that in
the FOH group, upregulated DEG clusters were mainly
involved in fatty acid metabolic process, ion homeosta-
sis, protein phosphorylation, membrane-enclosed lumen,
and response to nutrients (Additional file 1: Table S6),
while downregulated gene clusters were involved in
extracellular matrix, carbohydrate binding, regulation of
the system process, response to lipopolysaccharide, and
cell adhesion (Additional file 1: Table S7). Some import-
ant genes listed and summarized in Tables 3, 4 and 5.
Validation of RNA-seq data by quantitative RT-PCR
To verify the RNA-seq data, the expression of selected
genes involved in lipid metabolism and inflammatory
immune response were examined by quantitative real-
time RT-PCR (qRT-PCR). The WD feeding significantly
increased the expression of sterol regulatory element
binding factor 1 (Srebf1), suppressor of cytokine signal-
ing 2 (Socs2), monocyte chemoattractant protein 1
(Mcp1) and semaphorin 4A (Sema4a), and brain and
muscle ARNT-like protein 1 (Bmal1) whereas the regu-
latory effects of WD were significantly reversed by intake
of fish oil (Figs. 3 and 4). Moreover, WD feeding down-
regulated the expression of fatty acid synthase (Fasn)
and stearoyl-Coenzyme A desaturase 1 (Scd1), whereas
the expression in the FOH group was further decreased
(Fig. 3). Additionally, WD feeding decreased the expres-
sion level of period gene 2 and 3 (Per2 and Per3) , and
the effects were rescued by fish oil feeding (Fig. 4). The
results of qPCR were consistent with our RNA-seq data.
Discussion
This study was focused on the protective effects of n-
3 PUFA-rich (e.g. DHA and EPA) fish oil against
WD-induced NAFLD. To get a better observation of
the protective effects of fish oil, we fed WD animals
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with high-dose fish oil (10 % [w/w] in diet) for
16 weeks. In this study, we applied a next-generation
high-throughput sequencing technology to investigate
the difference of hepatic mRNA expression profile be-
tween WD-fed NAFLD rats and FOH-fed rats. Our
findings demonstrated that fish oil consumption res-
cued the effects of WD on the hepatic fatty acids and
cholesterol accumulation, metaflammation and rhythm
disturbance, suggesting that high dose fish oil supple-
ment may be useful for clinical NAFLD treatment.
n-3 PUFA improved hepatic lipid metabolism
TG ectopic accumulation in liver plays a central role in
the development of NAFLD. In the present study, the
plasma lipid analysis and Oil red staining showed that
16 weeks of fish oil feeding significantly reduced plasma
TG and hepatic steatosis compared with the WD group.
Additionally, our transcriptomic study compared the
hepatic mRNA expression level between FOH group and
WD group, and Gene Oncology (GO) annotation
enriched a number of DEGs connected to fatty acids
Fig. 1 Effects of different diets on rat liver steatosis and inflammation. Male SD rats were fed with normal chow diet, WD, or FOH for 16 weeks, and their
liver tissue sections were stained with Hematoxylin and Eosin (H&E, A-F) staining and Oil-red staining(G-I) respectively, and hepatic cytokine expression of
TNFα and IL-1β were examined by western blotting (J). The representative photographs as follow: (A-C) H&E staining photomicrographs of the CON, WD
and FOH group liver sections (×100), respectively; (D-F) H&E staining photomicrographs of the CON, WD and FOH group liver sections (×200), respecitvely;
(G-I) Oil-red staining photomicrographs of the CON, WD and FOH group liver sections (×100), respectively; (J) Differentially expressed level of hepatic TNFα
and IL-1β in each groups, β-actin were used as internal control
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metabolism (Table 3, 4). More than one fourth of liver
TG are synthesized de novo [17]. SREBP1c, encoded by
the gene Srebf1, plays a crucial role in de novo lipogen-
esis. Our transcriptomic results demonstrated that the
WD raised the expression of Srebf1, while the fish oil
feeding abrogated this effect and the Srebf1 expression
was normalized to the level similar to the control diet
group. Meanwhile, the mRNA levels of SREBP1c down-
stream genes involved in de novo lipogenesis, such as
Elovl5, Fads1/2 and Scd1 in FOH group were dramatic-
ally lower than the WD group (Additional file 1: Table
S4, S5, and Fig. 3). Several studies also indicated the in-
hibitory effects of fish oil on high-fat diet-induced
SREBP1c overexpression [18, 19]. The suppressive ef-
fects of PUFAs on SREBP1c was occurred at post-
transcriptional level [20]. Interestingly, the expression
level of insig2 in FOH group is similar to that in CON
group and significantly lower than that in WD group
(Additional file 1: Table S4, S5). This finding was con-
sistent with the effects of DHA on hepatocyte in vitro
[21]. When animal insulin levels are high, INSIG2 im-
proves SREBP1c cleavage and mature in Golgi, and
Insig2 itself undergoes ubiquitin related proteasomal
degradation [22, 23]. The differentially expressed Srebf1
and Insig2 between CON, WD and FOH groups suggest
that high fat feeding induced de novo lipogenesis mainly
attributed to highly Srebf1 expression in rats but not
hyperinsulinemia induced SREBP1c mature, and the
process was rescued by fish oil feeding. Consistently,
neither high-fat WD nor fish oil feeding showed the ef-
fects on fasting plasma glucose, and other studies also
pointed out that rats are more tolerant to high-fat-diet–
induced insulin resistance [24].
Besides the de novo lipogenesis, the expression of
genes involved in liver lipid uptake from the circulation
(CD36 and slc27a2) [17], fatty acids beta-oxidation in
the mitochondria (Cpt1a, Cpt2, Acadl, and Acaa1b) and
TG export (Apob and Mttp) [25, 26] were regulated by
fish oil feeding. These findings imply that fish oil can
promote hepatic fatty acids beta-oxidation and TG ex-
cretion, contribute to the amelioration of liver steatosis
(Fig. 1, Table 3).
Beside the hepatic triglycerides metabolism, fish oil
rich in n-3 PUFAs improved hepatic cholesterol metab-
olism (Table 4). In the present study, 16-week WD (2 %
cholesterol, w/w) feeding induced hypercholesterolemia
and hepatic cholesterol overload in SD rats, and fish oil
feeding significantly reduced the cholesterol content in
blood, particularly in the form of LDL-C (Table 1). In
the transcriptomic results, a series of DEGs between
CON vs. WD or FOH vs. WD group were enriched in
cholesterol metabolism pathways. Though both high cal-
oric diets intake decreased the expression of key rate-
limiting enzyme in cholesterol synthesis: 3-hydroxy-3-
methylglutaryl- coenzyme A reductase (HMGCoAR) in
the liver, fish oil consumption regulated the hepatic ex-
pression of a serial of genes related to cholesterol
Fig. 2 MA plot of differentially expressed genes identified in WD/CON and FOH/WD rat livers. Data represent individual gene responses plotted
as log2 fold-change versus base Mean fold-change >2 (P < 0.01), with a negative change representing the downregulated genes and a positive
change representing the upregulated genes
Table 2 NAFLD activity score (NAS)
CON WD FOH
Steatosis(n) 0(6) 2(1)3(5) 0(2)1(4)
Lobular inflammation(n) 0(6) 2(2)3(4) 1(5)2(1)
Hepatocellular ballooning(n) 0(6) 2(4)3(2) 1(4)2(2)
NAS 0 7.83 3.17
Fibrosis(n) 0(6) 2(6) 1(5)0(1)
NAFLD activity scores (NAS): the unweighted sum of steatosis, lobular
inflammation, and hepatocellular ballooning, NAS of >5 correlated with a
diagnosis of NASH.
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transport, including: Fat/CD36, Lox1 and Scarb1 [27,
28], which were associated with cholesterol uptake;
Abcg5/8, which were involved in cholesterol excretion
[29]; and Cyp7a1 and Cyp27a1, which were connected
to bile acid excretion [30].
Interestingly, our transcriptomic data indicated that
WD feeding reduced the expression of pcsk9 and ldlr
compared with CON group, while the fish oil
consumption furtherly inhibited the expression of
pcsk9 (Fig. 3). Proprotein convertase subtilisin/kexin
type 9 (PCSK9) plays an important role in degrad-
ation of LDLR, and it is thought a valuable treatment
target of hypercholesterolemia [31, 32]. A recent clin-
ical study has indicated that fish oil supplement could
reduce plasma PCSK9 level in women [33]. Our find-
ing suggests that fish oil may protect against WD-









Cholesterol synthesis Pmvk phosphomevalonate kinase 2.9 ↓ 1.22 ↓
Fdps farnesyl diphosphate synthase 6.97 ↓ 1.66 ↓
Nsdhl NAD(P) dependent steroid dehydrogenase-like 1.95 ↓ 1.41 ↓
Dhcr7 7-dehydrocholesterol reductase 3.13 ↓ 1.22 ↓
Cholesterol-rich lipoprotein uptake Ldlr LDL receptor 2.56 ↓ 1.13 ↑
Olr1/LOX-1 oxidized low density lipoprotein (lectin-like) receptor 1 60.48 ↑ 6.70 ↓
Scarb1/ SR-
BI
Scavenger receptor class B type I (SR-BI) 1.10 ↑ 1.37 ↓
CD36 Cluster differentiation protein 36 1.05 ↓ 2.07 ↑
Cholesterol secretion Abcg1 ATP-binding cassette, subfamily G (WHITE), member 1 3.57 ↑ 1.54↑
Abcg5 ATP-binding cassette, subfamily G (WHITE), member 5 1.48 ↓ 1.93↑
Abcg8 ATP-binding cassette, subfamily G (WHITE), member 8 7.24 ↓ 2.7 1↑
Intracellular metabolism to oxysterols and bile
acids
Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 1.53 ↓ 1.98↑
Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide
1
1.14 ↓ 1.08↑
Table 3 N-3 PUFA improved hepatic lipid metabolism in FOH group.
Category/Function Gene symbol /
Gene alias
Gene name Fold change
WDvs. CON FOH vs. WD
Fatty Acid Transport Slc27a1/FATP-1 solute carrier family 27 (fatty acid transporter), member1 1.48 ↑ 0.85↓
Slc27a2/ FATP-2 solute carrier family 27 (fatty acid transporter), member 2 1.17 ↑ 1.40↑
Cd36 fatty acid translocase (FAT/CD36) 1.05↓ 2.07↑
Fatty Acid Synthesis Srebf1/SREBP1c sterol regulatory element binding transcription factor 1 1.72↑ 2.27↓
Fasn fatty acid synthase 8.54↓ 1.99↓
Acaca acetyl-CoA carboxylase alpha 3.10↓ 1.17↑
Elovl5 ELOVL fatty acid elongase 5 1.31↓ 2.26↓
Fads1 fatty acid desaturase 1 6.28↓ 2.87↓
Fads2 fatty acid desaturase 2 3.26↓ 2.32↓
Scd1 stearoyl-Coenzyme A desaturase 1 1.49↓ 2.64↓
Fatty Acid Degradation Ppara/PPARα peroxisome proliferator activated receptor alpha 1.48↓ 1.31 ↑
Cpt1a carnitine palmitoyltransferase 1a, liver 1.08↑ 1.53↑
Cpt2 carnitine palmitoyltransferase 2 1.01↑ 1.42↑
VLDL Secretion Mttp microsomal triglyceride transfer protein 1.29↓ 1.23↑
Apob apolipoprotein B 1.11↓ 1.26↑
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Gene name Fold change
WDvs.CON FOHvs.WD
CD family Cd8a CD8 antigen, alpha polypeptide (p32) 2.53 ↑ 1.78 ↓
Cd44 CD44 antigen 3.37 ↑ 1.66 ↓
Cd81/
TAPA-1
CD81 antigen; target of antiproliferative antibody 1 1.17 ↑ 1.08 ↓





chemokine (C-C motif) ligand 2; monocyte chemoattractant protein 1 5.73 ↑ 2.12 ↓
Cxcl1/
GROa
chemokine (C-X-C motif) ligand 1; growth-regulated oncogene, alpha 5.26 ↑ 3.92 ↓
Cxcl9/
MIG
chemokine (C-X-C motif) ligand 9; monokine induced by interferon-gamma 1.38 ↑ 2.10 ↓
Cxcl16 chemokine (C-X-C motif) ligand 16 3.25 ↑ 1.66 ↓
Cxcr3 chemokine (C-X-C motif) receptor 3 2.24 ↑ 1.29 ↓
Cxcr4 chemokine (C-X-C motif) receptor 4 1.75 ↑ 1.58 ↓
Semaphorins, plexins and neuropilins Sema4a sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and short cytoplasmic domain, (semaphorin) 4A
1.87 ↑ 1.29 ↓
Sema4d sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and short cytoplasmic domain, (semaphorin) 4D
2.30 ↑ 1.29 ↓
Sema6b sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6B
2.29 ↑ 1.27 ↓
Plxnd1 plexin D1 1.38 ↑ 1.10 ↓
JAK-STAT-SOCS pathway Jak2 Janus kinase 2 (a protein tyrosine kinase) 1.23 ↑ 1.05 ↓
Jak3 Janus kinase 3 (a protein tyrosine kinase, leukocyte) 1.95 ↑ 1.09 ↓
Stat3 signal transducer and activator of transcription 3 (acute-phase response
factor)
1.40 ↑ 1.33 ↓
Stat5b signal transducer and activator of transcription 5B 1.48 ↑ 1.33 ↓
Socs1 suppressor of cytokine signaling 1 5.09 ↑ 7.06 ↓
Socs2 suppressor of cytokine signaling 2 3.46 ↑ 1.39 ↓
IFN pathway Irf1 interferon regulatory factor 1 2.07 ↑ 1.40 ↓
Irf5 interferon regulatory factor 5 1.71 ↑ 1.18 ↓
TNFα and TGFβ pathways Ltb lymphotoxin beta (TNF superfamily, member 3) 1.99 ↑ 2.19 ↓
Tnfrsf14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry
mediator)
3.99 ↑ 1.70 ↓
Tnfrsf1b tumor necrosis factor receptor superfamily, member 1B 1.56 ↑ 1.07 ↓
Traf7 TNF receptor-associated factor 7 1.94 ↑ 1.67 ↓
Tgfb1 transforming growth factor, beta 1 2.31 ↑ 1.02 ↓
Tgfbr2 transforming growth factor, beta receptor II (70/80 kDa) 1.30 ↑ 1.21 ↓
NFκB pathway Ikbkb inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 1.21 ↑ 1.05 ↓
Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 1.45 ↑ 1.19 ↓
Nfkb2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/
p100)
1.95 ↑ 1.33 ↓
Toll-like receptors and
lipopolysaccharide signaling pathway
Tlr2 toll-like receptor 2 1.86 ↑ 1.02 ↓
Cd14 CD14 antigen (lipopolysaccharide receptor) 1.50 ↑ 1.16 ↓
Litaf lipopolysaccharide-induced TNF factor 2.47 ↑ 1.54 ↓
Matrix proteases Mmp9 matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV
collagenase)
6.03 ↑ 2.05 ↓
Yuan et al. Lipids in Health and Disease  (2016) 15:20 Page 7 of 13
induced hypercholesterolemia via reducing the hepatic
psck9 expression. The effects of fish oil on PCSK9 is
worthy further study.
Circadian clocks modification may contribute to the
protective effects of fish oil on hepatic lipid metabolism
Our study confirmed the previous findings that n-3
PUFAs can ameliorate high-fat-diet–induced hepatic
lipid accumulation [34]. However, how fish oil protects
the liver against lipid and cholesterol metabolism dis-
order is still unclear. Circadian clock plays a crucial role
in metabolism and energy regulation, and the GO en-
richment analysis presented several DEGs between FOH
and WD group were associated with circadian clock
modification. Period genes (Pers) are in charge of nega-
tive feedback loop of circadian clock control, as well as
the Bmal1 plays the central role in circadian gene tran-
scription regulation [35]. In our study, the expression of
both per2 and per3 were decreased in the WD group,
and the expression of Bmal1 was increased, which may
lead to disruption of circadian clock and metabolic dis-
order, and the disturbed expression of per2, per3 and
Bmal1 were all rescued by fish oil feeding (Fig. 4). Our
RNA-seq data suggests that fish oil may protect the liver
against NAFLD via modification of the circadian clocks.
n-3 PUFA ameliorated hepatic inflammation
High fat diet induced chronic low-grade inflammation in
liver, known as metaflammation [36]. The histological
staining and western blotting analysis illustrated that the
fish oil intake partly alleviated WD-induced inflamma-
tory cells infiltration pro-inflammatory cytokines expres-
sion in liver (Fig. 1 A-F, J). The transcriptomic analysis
enriched a set of DEGs involved in inflammation such as
chemokine synthesis, bacteria response, and extracellular
matrix accumulation were upregulated, whereas n-3
PUFAs consumption reduced the expression of genes re-
lated to CD, chemokines and their receptors, semaphor-
ins and their receptors, JAK-STAT-SOCS pathway,
interferon pathway, NFκB pathways, and TLR pathways
(Table 5). Similar to the findings of Ito et al., WD intake
raised the expression of Ccl2, which plays an important
role in hepatic steatosis and inflammation [37]. The ex-
pression of Ccl2 was reduced in the FOH group com-
pared with the WD group, suggesting that the
modification of Ccl2 expression might contribute to the
hepatoprotective effects of n-3 PUFA. Egan et al. showed
that Cd44, an adhesion molecule in charge of cell migra-
tion, is associated with the leukocyte recruitment in a
lithogenic diet-induced hepatic steatosis[38]. In the
present study, the expression of Cd44 in the FOH group
was lower than WD group, implying that n-3 PUFAs re-
duce the hepatic inflammatory cell infiltration in WD-
induced NAFLD. Bertola et.al [39] found that the ex-
pression of inflammatory factors in plexin/semaphorin
family was significantly increased in NASH patients, and
in this study, n-3 PUFA feeding restored WD-induced
expression of T-helper 1 leukocyte differentiation-related
Sema4a and T-leukocyte activation-related Sema4d. We
found that the expression of Socs2, a key molecule in
JAK-STAT-SOC pathway, was elevated in the WD group,
and the expression in FOH group was lower than the
WD group, which is consistent with the results of Zad-
jali et.al. [40], suggesting that n-3 PUFA might protect
against diet-induced NAFLD via JAK-STAT-SOC path-
way. These findings suggests that fish oil protect liver
against WD-induced metaflammation mainly via sup-
pressing the infiltration and activation of hepatic
lymphocytes.
Conclusions
The present study demonstrated that chronic WD intake
induced hepatic TG accumulation, hepatocellular lipid
and cholesterol metabolic chaos, metaflammation and
fibrogenesis in the progress of NAFLD. The n-3 PUFA
intake compensated for WD-induced steatosis and de-
pressed hepatic inflammation, which contribute to the
amelioration of diet-induced NAFLD progress. The re-
sults suggest that n-3 PUFAs might be a potential diet-
ary therapeutic tool against NAFLD.
Methods
Animals
Male Sprague–Dawley rats (8–9 weeks old weighing
180 ~ 200 g) were purchased from Tonji Medical College
of Huazhong University of Science and Technology
(Wuhan, China). They were housed five per cage and
maintained in a 12-hour day/night cycle and kept under
standard laboratory conditions with a room temperature
of 22 °C ± 1 °C, relative humidity 60 % ±10 %, and 20 air
changes per hour. The rats were acclimatized to labora-
tory conditions for 1 week before the experiment and
randomly allocated to three groups of 10 animals each
fed for 16 weeks: normal chow diet[41] with 10 kcal% fat
Table 5 N-3 PUFA reduced liver inflammation in FOH group (Continued)
Mmp14 matrix metallopeptidase 14 (membrane-inserted) 1.30 ↑ 1.02 ↓
Plat/tPA plasminogen activator, tissue 2.15 ↑ 1.53 ↓
Plau/
uPA
plasminogen activator, urokinase 1.50 ↑ 1.66 ↓
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Fig. 3 qRT-PCR results of selected genes. The mRNA expression levels of selected genes involved in hepatic fatty acid (A), cholesterol (B)
metabolism and liver inflammation (C) were examined by qRT-PCR. Values are expressed as mean ± SD; n = 10 in each treatment group. a P < 0.05
vs. CON group; b P < 0.05 vs. WD group.
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(CON group), Western style lard-rich diet with 45 kcal%
fat and 2 % cholesterol (w/w) (WD group), or fish-oil-
rich diet with 10 % fish oil (w/w) and a total 45 kcal% fat
with 2 % cholesterol (w/w) (FOH group). Pure fish oil
(Coland, China) was obtained from anchovy. The ani-
mals were given water and diet ad libitum. This animal
study was conducted according to the Guidelines for the
Care and Use of Experimental Animals, and the protocol
was approved by Laboratory Animal Ethics Committee
of Wuhan Polytechnic University (ID Number:
20121009006).
The diets followed AIN93’s recommendations. Add-
itional file 1: Table S1 lists the nutrient composition, en-
ergy ratio, and fatty acid compositions in different
feedstuff. At the end of 16th week of the study, 12-hour
fasted rats were sacrificed with CO2 suffocate[42]. Blood
was collected into a heparinized tube (6–8 mL) and cen-
trifuged at 1000 × g for 15 min at 4 °C, and plasma was
collected and stored at −80 °C until analysis. The liver
was quickly removed, rinsed with 0.9 % sodium chloride
solution and weighed; a portion of the right hepatic lobe
was either frozen in liquid nitrogen and kept at −80 °C,
or fixed in 10 % neutral-buffered formalin and embed-
ded in paraffin for histological studies.
Plasma glucose, triacylglycerol (TG), total cholesterol
(Tch), high-density lipoprotein cholesterol (HDL-C), and
low-density lipoprotein cholesterol (LDL-C) concentra-
tions were measured using spectrophotometric clinical
assays, and enzymatic activities of plasma alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
were tested according to the protocol. All assays kits
were bought from Nanjing Jiancheng Institute of Bio-
logical Engineering (Nankin, China). All tests were con-
ducted according to the standard process by
spectrophotometry (Beckman, Inc., USA).
Histological studies
Fresh liver samples from the right lobe were either fro-
zen and stained with Oil Red O or fixed in 10 % neutral-
buffered formalin and embedded in paraffin and sec-
tioned at 5-μm thickness, stained with hematoxylin and
eosin (H&E). Histological steatosis and inflammation
were assessed semi-quantitatively by a pathologist who
was blinded to the experimental protocol, according to
the scoring system proposed by Kleiner et al.[43].
Western blot analysis
Total protein extraction from rat livers was performed
according to a commercially available kit (23252; Pierce™
Microplate BCA Protein Assay Kit, USA). Equal
amounts of protein (40–80 μg) were separated by 10 %
SDS-PAGE and electro-transferred to a PVDF mem-
brane (Millipore). Membranes were blocked, and then
incubated with antibodies overnight, such as, anti-IL-1β
(1:500, H-153; sc-7884; Santa Cruz), anti-TNFα (1:500,
L-19; sc-1351; Santa Cruz), anti-β-actin (1:500, C4; sc-
47778; Santa Cruz), and then with the horseradish
peroxidase-conjugated secondary antibody for 2 h. Spe-
cific protein expression levels were normalized to β-
actin for total protein analyses. The blot was detected
Fig. 4 Effects of diets on Per2,Per3 and Bmal1 expression. The mRNA expression levels of per2, per3 and Bmal1 were examined by qRT-PCR. Values
are expressed as mean ± SD; n = 10 in each treatment group. a: vs CON group; b: vs WD group, P < 0.05
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with the ChemiDoc™ MP System detection system (Bio-
Rad Laboratories, Inc). The experiments were replicated
three times. The membranes were scanned and the sum
optical density was quantitatively analyzed by Image Lab
software (Bio-Rad Laboratories, Inc).
RNA isolation, library preparation, and sequencing
Total RNA isolated from livers (liver tissues of ten rats
per group were pooled together) was treated with RQ1
DNase (Promega, Madison, WI) to remove DNA. The
pooled sample for each group was prepared using an
equal amount of total RNA from each individual . Polya-
denylated mRNAs were purified and concentrated with
oligo(dT)-conjugated magnetic beads (Invitrogen, Carls-
bad, CA) before use for directional RNA-seq library
preparation. Purified mRNAs were iron-fragmented at
95 °C followed by end repair and 5' adaptor ligation,
followed by reverse transcription with RT primer har-
boring 3' adaptor sequence and randomized hexamer.
The cDNAs were purified and amplified and PCR prod-
ucts corresponding to 200–500 bps were purified, quan-
tified, and stored at −80 °C until used for sequencing.
For high-throughput sequencing, the libraries were pre-
pared following the manufacturer’s instructions and ap-
plied to Hiseq 2000 system for 100 nt pair-end
sequencing by ABlife (Wuhan, China).
RNA-seq raw data clean and alignment statistics
Raw reads were first discarded if they contained more
than 2-N bases, and the reads were processed by clip-
ping adaptor and removing low-quality bases. Very short
reads (less than 20 nt) were also dropped. FASTX-
Toolkit (Version 0.0.13) was used to obtain clean reads.
The clean reads were aligned to the reference genome
by bowtie[44] or Tophat[45]. Based on the gene annota-
tion of the genome, the aligned reads with more than
one genome location were discarded due to their am-
biguous location. Uniquely localized reads were used to
calculate the number of reads and RPKM value (RPKM
represents reads per kilobase and per million) for each
gene, according to the genome location of reads and
genes. Other statistical results, such as gene coverage
and depth, distribution of reads around start and stop
codons, were also obtained.
Differentially expressed gene analysis
DEGs between the test and control samples were ana-
lyzed using edgeR [46], one of the R packages. For each
gene, the p-value was computed and the significance
threshold to control FDR at a given value was calculated.
The fold-changes were also estimated within the edgeR
statistical package.
Functional enrichment analysis
The lists of differentially expressed genes were submitted
to DAVID web server (https://david.ncifcrf.gov/) for en-
richment analysis. The enrichment clusters were sorted
by the enrichment score on descending order. The cat-
egories of one cluster were sorted by P-value in descend-
ing order. Fold Enrichment, Bonferroni and Benjamini
corrected P-value and FDR were also presented for each
category of each cluster.
Validation of DEGs by qRT-PCR
To evaluate the repeatability and reproducibility of
gene expression data obtained by RNA-Seq, an qRT-
PCR assay using SYBR Green chemistry (SYBR® qPCR
Mix, Rox; TAKARA Biotechnology, Dalian, China).
The isolated RNA of individual samples was reverse-
transcribed into cDNA using high-capacity reverse
cDNA transcription kit (Applied Biosystems, Foster
City, CA) in a total volume of 20 μL containing 1 μg
of total RNA, following the manufacturer’s instruc-
tions. PCR primers were designed using Primer Ex-
press software (Applied Biosystems). Additional file 1:
Table S2 shows the PCR primers sequences. Rat
GAPDH was simultaneously used as endogenous con-
trol gene. Each SYBR green-based real-time PCR re-
action contains, in a final volume of 14 μl, cDNA
from 14 ng of reverse-transcribed total RNA, 2.33
pmol primers, and 7 μl of 2× SYBR Green PCR Mas-
ter Mix (Applied Biosystems). Triplicate PCR reac-
tions were carried out in 96-well plates using 7500
Real-Time PCR System (Applied Biosystems). The
conditions were 50 °C for 2 min, 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for
1 min. The gene expression level was normalized to
that of invariable control gene, GAPDH. Data are
presented as minus Δ cycle threshold Ct.
Statistical analysis
Data are presented as mean ± SD. One-way ANOVA and
Tukey’s honestly significant difference post hoc analysis
were conducted to establish significant differences. All ana-
lyses were performed by SPSS 19.0 statistical software. Dif-
ferences were considered statistically significant at P < 0.05.
Additional file
Additional file 1: Table S1. The nutrient composition, energy ratio and
fatty acid profiles of experimental diets. Table S2. Primers used in this
study. Figure S3. The weekly body weight change of experiment
animals. Table S4. Differentially expressed genes between WD group and
CON group. Table S5. Differentially expressed genes between FOH
group and WD group. Table S6. Upregulated DEGs (FOH vs. WD)
implicated in the enrichedgene ontology processes. Table S7.
Downregulated DEGs (FOH vs. WD) implicated in the enrichedgene
ontology processes. (ZIP 236 kb)
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